Guillaume Vogin, MD, PhD

Guillaume Vogin, MD, PhD is professor at Lorraine and Luxemburg Universities, board certified in radiation oncology at the national radiotherapy center of Luxembourg. He has specialized in particle radiotherapy, sarcoma, pediatrics and CNS malignancies. He owns an expertise for the patients who underwent unusual radiation toxicity. He investigates cutting edge basic research in RNA biology in order to decipher the production and splicing of RNA – either coding or noncoding – induced by radiation. He recently joined Luxemburg Institute of Health.

GV obtained his master degree at Harvard Medical School/Brigham & Women’s Hospital and his PhD at the Cancer Research Centre of Lyon. Collectivelly, he demonstrated that the velocity and efficiency of pATM nuclear activation correlated with the severity of radiation toxicity. He participates to the developpment of predictive assays of IRS. GV is actually implementing 10 regional and national projects in the topic of diagnostic biomarkers of IRS and radiomics applied to radiation toxicity.

As a teacher, GV is leading a European program developping innovative multi professional educational initiatives applied to radiation oncology.

GV is the author of 60+ original peer-reviewed papers and 4 book chapters and monographs. GV is the recipient of several French and European awards (Académie de Stanislas, Fondation des Treilles, Société Française de Pédiatrie, Renaissance Française, Lucien Mallet Medal, Fondation Nuovo-Soldati). He is member of the French Society of Radiation Oncology, the French Society of Pediatric Oncology, the European Society of Therapeutic Radiation Oncology and the International Aerospace Medical Association

Disclosures:

• Employment: none
• Compensation: none
• Ownership: none
• Leadership: none